Earlier on Monday, FDA Accepted Takeda's Application Under Priority Review for Zasocitinib (TAK-279) For Moderate-To-Severe Plaque Psoriasis, With PDUFA Action Date in Q1 2027

뉴스 본문을 불러오고 있어요.

Earlier on Monday, FDA Accepted Takeda's Application Under Priority Review for Zasocitinib (TAK-279) For Moderate-To-Severe Plaque Psoriasis, With PDUFA Action Date in Q1 2027 | 웨이프 WAPE

Earlier on Monday, FDA Accepted Takeda's Application Under Priority Review for Zasocitinib (TAK-279) For Moderate-To-Severe Plaque Psoriasis, With PDUFA Action Date in Q1 2027

기사 요약

관련 종목

댓글 —